Sign in to view content

Evaluating Intravitreal ANX007, a Novel C1q Inhibitor, in the Treatment of GA Secondary to AMD: The ARCHER Study

David S. Boyer, MD

Video
Published 2021

Related

Assessing Commercially Available Cell Therapies for Retinal Disease in the U.S.
Ajay E Kuriyan, MD, MS
Daniel Simhaee, MD
Updates from the Field
2018
Effect of Initial Management With Aflibercept vs Laser Photocoagulation vs Observation on Vision Loss
Jennifer K. Sun, MD
Updates from the Field
2019
Ranibizumab for Radiation Retinopathy (RRR) A Prospective, Multicenter Trial of Monthly Versus PRN Dosing for Radiation Retinopathy-Related Macular Edema
Rajiv Anand, MD, FRCS, FASRS
Annual Meeting Talks
2018

Category: AMD-Non-Neovascular

See more